Friday, July 21, 2023
Sosei Heptares has announced the acquisition of Idorsia's Pharmaceuticals business in Japan and the Asia-Pacific region, excluding China. This strategic move marks a significant step towards Sosei Heptares' transformation into a fully integrated biopharmaceutical powerhouse.
Sosei Group's acquisition of Idorsia Pharmaceuticals Japan and Idorsia Pharmaceuticals Korea is set to bring significant expertise in drug development and commercialisation to Sosei Heptares, along with a strong market presence in Japan and the Asia-Pacific (APAC) region, excluding China.
As part of the transaction, Sosei Heptares will obtain select rights for Japan and APAC (ex-China) to two GPCR-targeted products: PIVLAZ® and daridorexant, and exclusive opt-ins for the Phase 3 cenerimod and lucerastat programmes.
Additionally, gain selected rights to up to five more clinical-stage programmes from Idorsia's development portfolio. This infusion of products and programmes will expand Sosei Heptares' drug pipeline and enhance its capabilities to develop and commercialise innovative medicines in the region.
The strategic transaction leverages three sources of innovation for Sosei Heptares: their own wholly owned discovery and early development pipeline, selected clinical candidates from Idorsia's pipeline, and in-licencing of clinical product candidates from third parties in Japan and APAC (ex-China).
One of the highlights of the acquisition is gaining rights to Idorsia's exciting pipeline of medicines, including the lead product PIVLAZ® (clazosentan), which has already been commercially launched and has seen rapid sales growth in Japan since its introduction in April 2022.
